MedTrace Logo

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

NCT06676579 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.

Conditions

  • IgA Nephropathy (IgAN)

Interventions

DRUG

Avacopan

Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.

DRUG

Prednisone

0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months

DRUG

Methylprednisolone (drug)

Methylprednisolone 1g intravenous on day +1

DRUG

Prednisolone

Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)

Sponsors & Collaborators

Principal Investigators

  • Fernando Fervenza, MD · Mayo Clinic, Rochester, MN

  • Nabeel Aslam, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-09
Primary Completion
2028-03-02
Completion
2029-03-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06676579 on ClinicalTrials.gov